Coronavirus (COVID-19) Update
AmerisourceBergen and our global businesses are highly engaged during the ongoing spread of the novel COVID-19 “Coronavirus."
June 27, 2018
US Bioservices now dispenses BRAFTOVI and MEKTOVI
The U.S. Food and Drug Administration recently approved BRAFTOVI (encorafenib) and MEKTOVI (binimetinib) for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation.